Burden and cost of LRTI: A methodologic overview

Infections in Medicine

Volumn 15, Issue 8 SUPPL. E, 1998, Pages 26-33

  McGuire, Alistair ^a,b  

^a CITY UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Burden of illness; Cost of illness; Lower respiratory tract infection (LRTI); Resistance; Treatment failure

Indexed keywords

EID: 0001888202     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Macfarlane JT, Colville A, Guion A, et al: Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 341:511-514, 1993.
2. Gray A, McGuire A, Fenn P: The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 12:1068-1076, 1995.
3. McGuire A, Gray A, Fenn P: The excess cost of primary care and treatment failure in the treatment of chronic bronchitis, mimeo. Health Economics Group, Institute of Health Sciences, University of Oxford. In press, 1998.
4. th National Morbidity Survey, (RCGP and ONS). London, England, 1992.
5. Guest J, Morris A: Community acquired lower respiratory tract infections: The annual cost to the National Health Service. Br J Med Econ 10:263-273, 1996.
6. Shlaes DM, Gerding DN, John JF Jr, et al: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25:584-599, 1997.
7. Quenzer RW, Pettit KG, Goldberg-Arnold RJ, et al: Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. Amer J Man Care 3:1027-1036, 1997.
8. Woodhead M, Grassi G, Huchon G, et al: Use of investigations in lower respiratory tract infection in the community: A European survey. Eur Respir J 9:1596-1600, 1996.
9. Huchon G, Grassi G, Leophone P, et al: Initial antibiotic therapy for lower respiratory tract infection in the community: A European survey. Eur Respir J 9:1590-1595, 1996.
10. Guest J, Morris A: Community acquired pneumonia: The annual cost to the National Health Service in the UK. Eur J Respir Med 10:1530-1534, 1997.
11. Davey P, Malek M, Parker S: Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics 6:409-437, 1992.
12. Backhouse R, Kapasi M, Noble I, et al: Modelling the use of three antibiotics in the management of community acquired pneumonia. Br J Med Econ 8:193-210, 1995.
13. Backhouse R, Shakespeare A, Hutton J: Economic evaluation of alternative antibiotic regimes in the management of acute exacerbations of chronic bronchitis. Br J Med Econ 8:11-25, 1995.
14. Wool C, Cerutti R, Garbagna N, et al: A cost-effective study of four different antibiotics in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Br J Med Econ 10:159-168, 1996.
15. Nightingale CH, Quintiliani R: Cost of oral antibiotic therapy. Pharmacotherapy 17(2):302-307, 1997.
16. Coast J, Smith R, Millar M: Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 5:217-226, 1997.
17. O'Brien T: Resistance of bacteria to antibacterial agents: Report of Task Force 2. Rev Infect Dis 9(suppl 3):S244-S260, 1987.
18. Levy S: Microbial resistance to antibiotics: An evolving and persistent problem. Lancet 2:83, 1982.
19. Kunin C: Resistance to antimicrobial drugs: A worldwide calamity. Ann Intern Med 118:557-561, 1993.
20. Neu H: The crisis in antibiotic resistance. Science 257:1050-1055, 1992.
21. Holmberg S, Solomon S, Blake P: Health and economic impacts of antimicrobial resistance. Rev Infect Dis 9:1065-1078, 1987.
22. US Office of Technology Assessment Report. Impacts of antibiotic-resistant bacteria, OTA-H-629, 1995.
23. Phelps C: CE bug/drug resistance: Sometimes less is more. Med Care 27:194-203, 1989.
24. Cargill K: Modelling the direct costs and future rates of antimicrobial resistance of Haemophilus influenza in lower respiratory tract infection. MSc dissertation, City University, London, England, 1997.